Insulin and insulin-like growth factor (IGF) signaling contribute to glucose metabolism and growth in a wide range of mammals \[[@B1]--[@B3]\]. IGF-I and insulin bind to both the IGF-I receptor (IGF1R) and insulin receptor (INSR) to activate the phosphorylation of IGF1R and INSR and also induce the phosphorylation of IR substrate (IRS), which is the docking protein for both INSR and IGF1R. Phosphorylated IRS proteins act as docking sites for several intracellular proteins such as Grb2, NcK, and the regulatory subunit p85 of phosphatidylinositol 3-kinase, which mediate the different actions of insulin and IGF1 \[[@B1]\]. There are six types of IRS (IRS1 to IRS6), and IRS1 and IRS2 are considered critical intracellular proteins for IGF/insulin signaling \[[@B1]--[@B3]\]. Numerous molecular studies have revealed that abnormality of the insulin/IGF signaling pathway induces insulin resistance and type 2 diabetes, especially in obese adults \[[@B4]--[@B6]\]. Specifically, obesity promotes a state of chronic low-grade inflammation attributed to the release of free fatty acids, glycerol, hormones (*e.g.*, leptin, adiponectin, and endothelin-1), and proinflammatory cytokines \[*e.g.*, tumor necrosis factor*α*, interleukin-1*β*, and interleukin-6\] from the adipose tissue; these events negatively regulate IRS kinase and induce abnormal signaling, resulting in insulin resistance.

Small-for-gestational-age (SGA) birth induces hypoglycemia in neonates and is associated with postnatal insulin resistance and type 2 diabetes in adults \[[@B7]--[@B9]\]. Hypoglycemia in SGA neonates is caused by inadequate glycogen stores, rapid disappearance rates of glucose, and higher insulin sensitivity \[[@B10]--[@B12]\]. Furthermore, postnatal insulin resistance in adult patients born as SGA neonates is associated with rapid postnatal weight gain \[[@B9], [@B13], [@B14]\] or decreased *β*-cell growth due to undernutrition \[[@B15]--[@B17]\]. Although these findings suggest abnormal insulin/IGF signaling in SGA neonates, the detailed mechanisms of both hypoglycemia and insulin resistance associated with SGA remain unclear. Real-time polymerase chain reaction (PCR) analysis is a useful tool for the detection of even small amounts of insulin/IGF signaling--related genes from cells or tissues. Several reports on insulin/IGF signaling have examined the placenta of SGA neonates using real-time PCR analysis of insulin/IGF signaling--related genes to determine insulin/IGF signaling abnormalities in the fetus \[[@B18], [@B19]\]; however, real-time PCR analysis of insulin/IGF signaling--related genes from SGA neonates has not been performed using cord blood, which better reflects the neonate status.

This is, to our knowledge, the first study to perform a quantitative real-time PCR analysis for evaluating the messenger RNA (mRNA) expression of insulin/IGF signaling genes, *IGF1R*, insulin receptor (*INSR*), *IRS1*, *IRS2*, and glucose transporters 2 and 4 (*SLC2A2* and *SLC2A4,* respectively) in umbilical cord blood.

1. Materials and Methods {#s9}
========================

A. Subjects and Measurement {#s10}
---------------------------

This study initially included neonates who were born between September 2015 and July 2016 at the Perinatal Medical Center of Tottori University Hospital. We performed this procedure after obtaining consent from their mothers. The inclusion criteria for neonates were term birth (gestational age at birth: 37 to 41 weeks), birth weight (BW) and length \<90th percentile based on Japanese neonatal anthropometric charts for gestational age, sex, and the mother's history of childbirth \[[@B20]\]. The exclusion criteria for neonates were preterm birth (gestational age ≤36 weeks), birth with asphyxia, and birth to mothers with gestational diabetes mellitus diagnosed based on a 75-g oral glucose tolerance test and treated with betamethasone, insulin, and antidiabetic drugs. The neonates of mothers with underlying diseases \[hyperthyroidism without antithyroid drugs (n = 1) and hypothyroidism treated with levothyroxine (25 µg/d; n = 1)\] were included. Neonates with malformations or genetic disorders were excluded. Finally, 57 newborns (28 males and 29 females) were recruited. Seventeen of them, who were full-term appropriate-for-gestational-age (AGA) neonates without hypoglycemia and maternal complications, were used as controls. SGA was defined as less than or equal to −2.0 standard deviations of BW and/or birth length on the chart \[[@B20]\]. We immediately measured the plasma glucose levels and serum levels of insulin and IGF-I from the cord blood (collected from the umbilical vein) at birth. The amended insulin-glucose ratios were calculated using the following formula: insulin (pmol/L)/\[glucose (mmol/L) -- 1.7 mmol/L\]. Hypoglycemia was defined as a plasma glucose level of \<50 mg/dL (\<2.8 mmol/L) within 48 hours of birth. If hypoglycemia was detected, treatments for hypoglycemia with feeding milk or intravenous glucose infusion were instituted. Neonatal mass screening for metabolic disorders was performed in all neonates, but no neonates with positive screening tests were detected. This study was approved by the Ethics Committee of Tottori University.

B. Quantitative Reverse Transcription PCR {#s11}
-----------------------------------------

The collected cord blood (from the umbilical vein) was immediately placed into a PAXgene Blood RNA Tube (Becton Dickinson and Company, Franklin Lakes, NJ); total RNA from the umbilical cord blood was purified using the reagents provided in the PAX gene Blood RNA Kit (QIAGEN, Germanton, MD) within 4 days, and reverse transcription PCR was performed. First-strand complementary DNA synthesis was performed as described previously \[[@B21]\]. Quantitative real-time PCR analysis was applied for evaluating the expression of *IGF1R*, *INSR*, *IRS1*, *IRS2*, *SLC2A2*, and *SLC2A4* mRNA using the Applied Biosystems 7900HT Fast Real-Time PCR System (Life Technologies Japan Ltd., Tokyo, Japan) with a TaqMan probe and 2× EXPRESS qPCR Supermix with Premixed ROX (Life Technologies, Carlsbad, CA). *β-Actin* was used as a control gene in AGA neonates with normoglycemia. TaqMan probes 22, 54, 52, 49, 85, 67, and 63 were used to detect *IGF1R*, *INSR*, *IRS1*, *IRS2*, *SLC2A2*, *SLC2A4*, and *β-actin*, respectively.

C. Statistical Analysis {#s12}
-----------------------

Statistical analysis was performed using R (version 3.2.5) and the R Commander package (R Foundation for Statistical Computing, Vienna, Austria). Differences between groups ([Table 1](#T1){ref-type="table"}) were assessed using nonparametric tests (Mann-Whitney *U* test) or Fisher's exact test. Moreover, the mRNA levels ([Figs. 1 and 2](#F1){ref-type="fig"}[](#F2){ref-type="fig"}) were compared using a parametric test (Welch *t* test) due to normal distribution. The results in [Table 1](#T1){ref-type="table"} are expressed as median and interquartile range, and those in [Figs. 1 and 2](#F1){ref-type="fig"}[](#F2){ref-type="fig"} are expressed mean ± standard error of the mean. A *P* value of \<0.05 was considered to indicate a statistically significant difference.

###### 

**Maternal and Neonatal Characteristics and Laboratory Data in Cord Blood Samples**

                                                     AGA Neonates \[Median (IQR)\]   SGA Neonates \[Median (IQR)\]   Power                                                                                                                                                                                                                                                                                                                           
  -------------------------------------------------- ------------------------------- ------------------------------- ------------------ ---- ------- ------------------ --- ------- ------------------------------------------------------- ---- ------- ------------------------------------------------------- --- ----------------------------------------- -------------------- --- ------- --------------------------------------------- ------ -----------------------------------------
  Maternal characteristics                                                                                                                                                                                                                                                                                                                                                                                                                           
   Age (y)                                           42                              32                              (30.0--36.0)       35   33      (30.8--36.5)       7   31      (27.0--36.0)                                            10   35      (32.5--37.3)                                            3   32                                        (31.5--33.5)         7   35      (34.5--38.5)                                  0.14   0.26
   Weight (kg)                                       41                              63.0                            (56.3--68.9)       35   63.2    (58.3--68.6)       6   63.8    (53.4--68.9)                                            8    55.2    (50.3--59.1)                                            2   49.5                                      (48.8--50.3)         6   56.1    (54.9--64.0)                                  0.46   0.06
  Delivery                                                                                                                                                                                                                                                                                                                                                                                                                                           
   Cesarean Section (n)                                                              11                                                 8            3                      6                                                               1            5                                                           0.05[*^a^*](#t1n1){ref-type="table-fn"}                                                                                         
  Neonatal characteristics                                                                                                                                                                                                                                                                                                                                                                                                                           
   Males (n, %)                                      42                              19                              (45.2%)            35   16      (45.7%)            7   3       (42.9%)                                                 10   6       (60%)                                                   3   0                                         (0%)                 7   6       (85.7%)                                              0.49[*^a^*](#t1n1){ref-type="table-fn"}
   Gestational age (wk)                              42                              39.0                            (37.4--40.5)       35   39.0    (37.9--40.4)       7   37.1    (37.1--37.4)[*^b^*](#t1n2){ref-type="table-fn"}         10   37.7    (37.4--38.2)[*^c^*](#t1n3){ref-type="table-fn"}         3   37.9                                      (37.4--38.0)         7   37.6    (37.4--38.3)                                  0.59   \<0.01
   BW (kg)                                           42                              2.95                            (2.70--3.17)       35   3.06    (2.82--3.16)       7   2.50    (2.34--2.58)[*^b^*](#t1n2){ref-type="table-fn"}         10   1.95    (1.90--2.00)[*^c^*](#t1n3){ref-type="table-fn"}         3   1.90                                      (1.73--1.95)         7   1.96    (1.93--2.09)                                  1.00   \<0.01
   BW SDS                                            42                              0.13                            (--0.57 to 0.67)   35   0.19    (--0.43 to 0.74)   7   −0.39   (--1.01 to --0.12)[*^b^*](#t1n2){ref-type="table-fn"}   10   −2.64   (--2.87 to --2.08)[*^c^*](#t1n3){ref-type="table-fn"}   3   −2.83                                     (--3.16 to --2.70)   7   −2.37   (--2.79 to --1.79)                            1.00   \<0.01
   Birth length (cm)                                 42                              48.1                            (46.7--49.1)       35   48.3    (47.5--49.3)       7   45.2    (44.0--45.7)[*^b^*](#t1n2){ref-type="table-fn"}         10   42.9    (41.9--43.0)[*^c^*](#t1n3){ref-type="table-fn"}         3   42.8                                      (41.9--42.9)         7   43.0    (41.9--43.5)                                  0.97   \<0.01
   Birth length SDS                                  42                              −0.39                           (--0.89 to 0.17)   35   −0.09   (--0.76 to 0.17)   7   −0.98   (--1.27 to 0.86)[*^b^*](#t1n2){ref-type="table-fn"}     10   −2.37   (--2.5 to --2.11)[*^c^*](#t1n3){ref-type="table-fn"}    3   −2.38                                     (--2.46 to --2.37)   7   −2.12   (--2.60 to --2.08)                            1.00   \<0.01
   Glucose (mg/dL)                                   39                              82                              (53--109)          32   89      (70--113)          7   39      (32--43)[*^b^*](#t1n2){ref-type="table-fn"}             10   41      (30--54)[*^c^*](#t1n3){ref-type="table-fn"}             3   60                                        (58--62)             7   33      (15--42)[*^d^*](#t1n4){ref-type="table-fn"}   0.90   \<0.01
   Insulin (μIU/mL)                                  38                              2.4                             (1.1--4.9)         31   2.9     (1.2--5.9)         7   2.0     (1.2--2.7)                                              10   1.5     (0.8--4.1)                                              3   1.7                                       (1.5--2.4)           7   0.9     (0.65--7.2)                                   0.90   0.49
   Amended insulin-glucose ratio (pmol/L)/(mmol/L)   39                              6.0                             (2.6--19.9)        32   5.0     (2.4--10.3)        7   16.4    (7.8--28.5)                                             10   15.2    (6.3--36.7)                                             3   6.4                                       (6.1--9.8)           7   35.8    (11.7--52.9)                                  0.47   0.08
   Cord IGF-I (ng/mL)                                38                              54                              (43--70)           31   55      (46--78)           7   44      (40--56)                                                10   20      (15--36)[*^c^*](#t1n3){ref-type="table-fn"}             3   16                                        (12--20)             7   25      (15--42)                                      0.89   \<0.01

Values are given as median (interquartile range). Normal range of amended insulin-glucose ratio is \<53.6.

Abbreviations: IQR, interquartile range.

*P* values from Fisher's exact test; other *P* values from Mann-Whitney *U* test.

*P* \< 0.05 between normoglycemia and hypoglycemia in AGA.

*P* \< 0.01 between all AGA and SGA.

*P* \< 0.01 between normoglycemia and hypoglycemia in SGA.

![Flow diagram of participants in this study.](js-01-1408-f1){#F1}

![Expression levels of mRNA in cord blood samples from AGA or SGA neonates. *IGF1R, INSR, IRS1, IRS2, SLC2A2,* and *SLC2A4* mRNA expression levels in cord blood samples from AGA (n = 42) and SGA (n = 10) neonates are measured using real-time PCR and analyzed using the 2^−ΔΔCt^ method. 2^−ΔΔCt^ = 2^-⊿⊿Ct^ = 2-(^⊿Ct^, for the target mRNA ^-⊿Ct^, for *β-actin*). The mean expression of *β-actin* mRNA in AGA neonates with normoglycemia (n = 17) is used as a control. The results are presented as mean ± SE (AGA, n = 42; SGA, n = 10). \**P* \< 0.05 (Welch *t*-test).](js-01-1408-f2){#F2}

2. Results {#s13}
==========

We analyzed 57 neonates (28 males and 29 females) who met our criteria ([Figure 3](#F3){ref-type="fig"}). Five neonates were excluded because of gestational diabetes mellitus in the mothers. Fifty-two neonates were eligible: 42 AGA and 10 SGA neonates. The clinical and maternal characteristics of the neonates are shown in [Table 1](#T1){ref-type="table"}. There was no difference in the maternal age and body weight between the AGA and SGA groups. The median BWs in the AGA and SGA groups were 2950 g (2700 to 3170 g) and 1950 g (1900 to 2000 g) (*P* \< 0.01), respectively.

![Expression levels of mRNA in cord blood samples from SGA and AGA neonates with normoglycemia or hypoglycemia. (A) *IGF1R, INSR, IRS1, IRS2, SLC2A2,* and *SLC2A4* mRNA expression levels in cord blood samples from SGA neonates are grouped according to glucose concentration measured using real-time PCR and are analyzed using the 2^−ΔΔCt^ method (normoglycemia, n = 3; hypoglycemia, n = 7). (B) *IGF1R, INSR, IRS1, IRS2, SLC2A2,* and *SLC2A4* mRNA expression levels in cord blood samples from AGA neonates are grouped according to glucose concentration measured using real-time PCR and are analyzed using the 2^−ΔΔCt^ method (normoglycemia, n = 31; hypoglycemia, n = 7). 2^−ΔΔCt^ = 2^-⊿⊿Ct^ = 2-(^⊿Ct^, for the target mRNA ^-⊿Ct^, for *β-actin*). The mean expression of *β-actin* mRNA in AGA neonates with normoglycemia (n = 17) is used as a control. The results are presented as mean ± SEM. \**P* \< 0.05 (Welch *t*-test).](js-01-1408-f3){#F3}

The plasma glucose levels in SGA neonates were significantly lower than those in AGA neonates \[SGA median: 41 mg/dL (2.27 mmol/L); AGA median: 82 mg/dL (4.56 mmol/L); *P* \< 0.01\]. Furthermore, 14 neonates (27% of eligible neonates; AGA, n = 7; SGA, n = 7) exhibited subsequent hypoglycemia, and the rate of subsequent hypoglycemia was significantly higher in the SGA group than in the AGA group (*P* = 0.003). Although the cord serum IGF-I levels in AGA neonates were significantly higher than those in SGA neonates (SGA median, 20 mg/dL; AGA median, 54 mg/dL; *P* \< 0.01), the cord serum insulin levels were similar between the AGA and SGA neonates (*P* = 0.9). The normal amended insulin-glucose ratio should be \<53.6 \[[@B22], [@B23]\]; both groups did not show a significant increase, and there were no significant differences. Four neonates (AGA, n = 1; SGA, n = 3) displayed relatively elevated insulin levels (\>2 μIU/mL) with hypoglycemia. Hyperglycemia was not observed in any of the neonates.

A. Comparison of mRNA Levels Between SGA and AGA Neonates {#s14}
---------------------------------------------------------

The mRNA expression of IRS2 was significantly increased in SGA neonates compared with AGA neonates (*P* = 0.013), but there were no differences in the expression of *IGF1R*, *INSR*, *IRS1*, *SLC2A2*, and *SLC2A4* mRNA ([Fig. 2](#F2){ref-type="fig"}). Furthermore, a simple linear regression analysis was performed to predict the relative expression of IRS2 mRNA in cord blood based on BW standard deviation score (SDS), glucose level, gestational age, and sex (Supplemental Fig. 1), and a significant regression equation (*P* = 0.0022) with an *R*^2^ of 0.176 was obtained only for BW SDS. In the participants, we predicted that the relative expression of IRS2 mRNA is equal to 1.18 to 0.21 (BW) when the BW is showed in SDS. SGA neonates with subsequent hypoglycemia exhibited significantly higher *IRS2* mRNA expression than did normoglycemic SGA neonates \[[Fig. 3(A)](#F3){ref-type="fig"}\], whereas the mRNA expression did not significantly differ between the subsequent hypoglycemic and normoglycemic subgroups \[[Fig. 3(B)](#F3){ref-type="fig"}\] of AGA neonates. However, results of the simple linear regression analysis between the relative expression of *IRS2* mRNA in cord plasma glucose levels were not significant (*P* = 0.65), with an *R*^2^ of 0.0045 (Supplemental Fig. 1). Furthermore, the increased mRNA expression of *SLC2A2* and *SLC2A4* in SGA neonates with subsequent hypoglycemia was not significant, and an increasing trend was observed in these neonates compared with normoglycemic neonates. We also performed the multiple linear regression analysis between three variables \[BW (SDS), glucose level, and gestational age\] and IRS2 mRNA separately in male and female. The significant regression equation (*P* = 0.033) with an *R*^2^ of 0.21 was obtained for BW in male, and the nonsignificant equation (*P* = 0.054) with an *R*^2^ of 0.3 was obtained for BW in female. There is no regression equation between IRS2 mRNA and all other variables (data not shown).

3. Discussion {#s15}
=============

In this study, the *IRS2* mRNA expression was significantly higher in the SGA neonates, especially in those with hypoglycemia. Moreover, the cord blood from the SGA neonates showed lower glucose and serum IGF-I levels, without hyperinsulinemia. To the best of our knowledge, this is the first study of *IGF1R*, *INSR*, *IRS1-2*, *SLC2A2*, and *SLC2A4* mRNA in cord blood.

Although insulin and IGF1 play distinct physiological roles in glucose metabolism and growth, both insulin and IGF signals use the same signaling pathways \[[@B1], [@B24]\]. Furthermore, insulin and IGF1 have both common and complementary effects \[[@B25]\]. Previous animal or human studies have demonstrated that SGA neonates have lower serum IGF1, insulin, and glucose levels \[[@B26]--[@B28]\]. Furthermore, higher insulin sensitivity is related to hypoglycemia in SGA neonates \[[@B27], [@B29]\]. From these findings, we expected the abnormal expression of mRNA to be related to the insulin/IGF signals of *IGF1R*, *INSR*, *IRS1-2*, *SLC2A2*, and *SLC2A4* in SGA neonates, which were evaluated in this study. We detected lower serum glucose and IGF1 levels in the SGA group, which is consistent with previous reports \[[@B26]--[@B28]\]; however, we observed no difference in the expression of *IGF1R*, *INSR*, *SLC2A2*, and *SLC2A4* in the SGA neonates, and the expression of only *IRS2* mRNA was significantly increased in these neonates, especially in those with subsequent hypoglycemia. Given that hyperinsulinemia decreases the expression of *INSR*, *IRS1*, and *IRS2* \[[@B30]--[@B32]\], our findings suggest that the SGA neonates did not exhibit hyperinsulinemia, at least in the fetal cord blood.

An explanation for why the cord blood from the SGA neonates showed increased *IRS2* mRNA expression is as follows. IRS1 and IRS2 are docking proteins for both IR and IGF1R \[[@B1], [@B31]\]. The activated phosphorylation of INSR and IGF1R by insulin or IGF1 binding induces the phosphorylation of IRS, resulting in intracellular signaling, which has an essential role in growth and metabolism \[[@B1], [@B2], [@B33]\]. Furthermore, the expression of *Irs2* mRNA and Irs2 protein was remarkably increased during 24-hour fasting and decreased rapidly after refeeding in normal mice \[[@B34]\]. These findings suggest that the increased expression of *IRS2* mRNA in SGA neonates is caused by fetal undernutrition, and the significant regression equation between the expression of *IRS2* mRNA and BW is consistent with these findings. Furthermore, the upregulation of IRS2 may play a role in the increased sensitivity to insulin \[[@B35]\]. Mohanty *et al*. \[[@B36]\] revealed that the overexpression of Irs2 in isolated rat islets significantly increased basal and [d]{.smallcaps}-glucose--stimulated insulin levels. These findings also indicate that the considerably increased *IRS2* mRNA expression in the SGA neonates with hypoglycemia in our study might be related to higher insulin sensitivity and hypoglycemia in SGA neonates, which has also been previously reported \[[@B27], [@B29]\]. Furthermore, the increased mRNA expression of *SLC2A2* and *SLC2A4* in SGA neonates with subsequent hypoglycemia was observed but was not significant. Glucose transporters GLUT2 (SLC2A2) and GLUT4 (SLC2A4) are thought to be activated by IRS2 \[[@B37], [@B38]\]. Accordingly, the increased IRS2 mRNA expression in SGA with subsequent hypoglycemia might induce the increased mRNA expression of *SLC2A2* and *SLC2A4*. Furthermore, GLUT2 and GLUT4 may be the downstream proteins in IRS2 signaling, and these finding may reflect the variation in mRNA expression of these proteins; however, further studies are needed.

Moreover, SGA is also associated with postnatal insulin resistance in adults \[[@B9], [@B12], [@B39]\], and these conditions are known as the fetal programming of diabetes (Developmental Origins of Health and Disease) \[[@B40]\]. The increased mRNA expression of IRS2, which is an important factor for insulin signaling, might be associated with this fetal programming, and we are planning to perform these experiments in infants, children, and adults.

A limitation of this study was the small number of assessed SGA neonates (n = 10). We intend to continue this study with more subjects comprising premature infants, neonates, and children.

In conclusion, we determined that SGA is associated with higher IRS2 mRNA expression without hyperinsulinemia. The increased expression of IRS2 mRNA might be associated with abnormal glucose metabolism, leading to hypoglycemia and postnatal insulin resistance in SGA neonates. Our study findings might aid in the elucidation of the abnormal glucose metabolism in SGA neonates.

Abbreviations: AGAappropriate-for-gestational-ageBWbirth weightIGFinsulin-like growth factorIGF1Rinsulin-like growth factor-I receptor*INSR*insulin receptorIRinsulin receptorIRSinsulin receptor substratemRNAmessenger RNAPCRpolymerase chain reactionSDSstandard deviation scoreSGAsmall-for-gestational-age.
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